Evidence map›Paper›PMID 40405306›Full record

ReviewStem cell research & therapy2025

Stem cell therapy: a revolutionary cure or a pandora's box.

Hany E Marei

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Adipose-derived and bone marrow aspirate concentrate injections for osteoarthritis: A scoping review.PM & R : the journal of injury, function, and rehabilitation · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Microneedle-Assisted Cell Delivery and Therapy.Research (Washington, D.C.) · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hany E MareiDepartment of Cytology and Histology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35116, Egypt. hanymarei@mans.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review article examines how stem cell therapies can cure various diseases and injuries while also discussing the difficulties and moral conundrums that come with their application. The article focuses on the revolutionary developments in stem cell research, especially the introduction of gene editing tools like CRISPR-Cas9, which can potentially improve the safety and effectiveness of stem cell-based treatments. To guarantee the responsible use of stem cells in clinical applications, it is also argued that standardizing clinical procedures and fortifying ethical and regulatory frameworks are essential first steps. The assessment also highlights the substantial obstacles that still need to be addressed, such as the moral dilemmas raised by the use of embryonic stem cells, the dangers of unlicensed stem cell clinics, and the difficulties in obtaining and paying for care for patients. The study emphasizes how critical it is to address these problems to stop exploitation, guarantee patient safety, and increase the accessibility of stem cell therapy. The review also addresses the significance of thorough clinical trials, public education, and policy development to guarantee that stem cell research may fulfill its full potential. The review concludes by describing stem cell research as a promising but complicated topic that necessitates a thorough evaluation of both the hazards and the benefits. To overcome the ethical, legal, and accessibility obstacles and eventually guarantee that stem cell treatments may be safely and fairly included in conventional healthcare, it urges cooperation between the scientific community, legislators, and the general public.

Indexed as

Cell- and Tissue-Based TherapyStem Cell ResearchStem Cell TransplantationAnimalsCRISPR-Cas SystemsEmbryonic Stem CellsGene EditingHumansAlzheimer’s diseaseBiotech investmentsCardiovascular regenerationClinical applicationsCommercializationCRISPR-Cas9Diabetes treatmentDisease modelingEmbryonic stem cells (ESCs)Ethical concernsFuture of stem cell therapiesGene editingHematopoietic stem cells (HSCs)Immune rejectionInduced pluripotent stem cells (iPSCs)Mesenchymal stem cells (MSCs)Neurodegenerative disordersOrganoidsOrgan transplantationParkinson’s diseaseRegenerative medicineRegulatory challengesReproducibility issuesSpinal cord injuryStandardization of protocolsStem cell researchTissue engineeringTumor formation riskUnregulated stem cell clinics

Identifiers

PMID40405306
PMCPMC12096755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.